Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDESA BIOTECH, INC.

(EDSA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
5.26(c) 4.87(c) 4.64(c) 4.46(c) 4.35(c) Last
236 413 201 873 131 521 155 918 127 471 Volume
+1.15% -7.41% -4.72% -3.88% -2.47% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -23,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,95x
Yield 2022 -
Sales 2023 122 M - -
Net income 2023 22,9 M - -
Net Debt 2023 - - -
P/E ratio 2023 4,61x
Yield 2023 -
Capitalization 58,8 M 58,8 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 0,48x
Nbr of Employees 16
Free-Float 72,1%
More Financials
Company
Edesa Biotech, Inc. is a Canada-based biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. It is organized under the laws of British Columbia, Canada. The CompanyÔÇÖs two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody... 
More about the company
Ratings of Edesa Biotech, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about EDESA BIOTECH, INC.
01/13Edesa Biotech Gets Canada Ok to Test COVID-19 Drug as Rescue Therapy
MT
01/13EDESA BIOTECH : Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
PU
01/13Edesa Biotech, Inc. Receives Canadian Approval to Test Covid-19 Drug as Rescue Therapy
CI
2021EDESA BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
2021Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021
CI
2021EDESA BIOTECH : Reports Fiscal Year 2021 Results - Form 8-K
PU
2021EDESA BIOTECH : Reports Fiscal Year 2021 Results
PU
2021HC Wainwright Starts Edesa Biotech at Buy With $16 Price Target
MT
2021EDESA BIOTECH : Marks Enrollment Milestone in Dermatitis Study
PU
2021Edesa Biotech, Inc. Marks Enrollment Milestone in Dermatitis Study
CI
2021EDESA BIOTECH, INC. : Entry into a Material Definitive Agreement, Financial Statements and..
AQ
2021Edesa Biotech Extends COVID-19 Clinical Study to Poland
PU
2021Edesa Biotech, Inc. Announces Polish Regulators Approves Clinical Trial Application for..
CI
2021EDESA BIOTECH : Says its COVID-19 Drug Candidate Reduces Mortality, Based on Phase 2 Study..
MT
2021EDESA BIOTECH : Reports Favorable Mortality Reductions in COVID-19 Study
PU
More news
News in other languages on EDESA BIOTECH, INC.
01/13Edesa Biotech obtient l'autorisation du Canada de tester le médicament COVID-19 comme t..
01/13Edesa Biotech, Inc. reçoit l'approbation du Canada pour tester le médicament Covid-19 c..
2021Edesa Biotech, Inc. annonce ses résultats pour l'année complète se terminant le 30 sept..
2021Edesa Biotech étend au Canada le recrutement de patients pour l'essai de phase 2b sur l..
2021Edesa Biotech déclare que le comité de sécurité indépendant approuve la poursuite de l'..
More news
Analyst Recommendations on EDESA BIOTECH, INC.
More recommendations
Chart EDESA BIOTECH, INC.
Duration : Period :
Edesa Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDESA BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,35 $
Average target price 18,00 $
Spread / Average Target 314%
EPS Revisions
Managers and Directors
Pardeep Nijhawan Chief Executive Officer & Director
Michael Brooks President
Kathi Niffenegger Chief Financial Officer
Sean A. MacDonald Chairman
Blair Gordon Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
EDESA BIOTECH, INC.-22.74%59
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624